Editorial
Overcoming resistance to third-generation epidermal growth factor receptor tyrosine kinase inhibitor in non-small cell lung cancer
Abstract
In the treatment of non-small cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) mutations, EGFR-tyrosine kinase inhibitor (EGFR-TKI) is a key drug that can prolong the survival of patients.
